Azithromycin during Routine Well-Infant Visits to Prevent Death

Area of Science:

• Global Health
• Pediatrics
• Infectious Diseases

Background:

• Mass azithromycin distribution reduces childhood mortality in some African regions, particularly in infants under 12 months.
• The effectiveness of routine infant healthcare visits for azithromycin administration in preventing infant death remains unclear.

Purpose of the Study:

• To evaluate the efficacy of single-dose azithromycin administered during infancy (5-12 weeks) via routine healthcare visits in preventing death before 6 months of age.
• To assess the impact of infant azithromycin on all-cause mortality in Burkina Faso.

Main Methods:

• A randomized, placebo-controlled trial involving 32,877 infants in Burkina Faso.
• Infants received either a single dose of azithromycin (20 mg/kg) or placebo during routine health visits.
• Primary endpoint was mortality before 6 months of age, with vital status assessed at 6 months.

Main Results:

• No significant difference in mortality was observed between the azithromycin group (82 deaths) and the placebo group (75 deaths) before 6 months of age.
• The hazard ratio for death was 1.09 (95% CI, 0.80 to 1.49), with no statistically significant effect found in prespecified subgroups.
• No difference in adverse events was noted between the two groups.

Conclusions:

• Administration of azithromycin to infants through the existing healthcare system in Burkina Faso did not prevent death.
• The findings suggest that this specific intervention strategy is not effective in reducing infant mortality in this context.